EGFR and non-small cell lung carcinoma: A Phase I/II, open-label, multicenter, dose-escalation, multi-cohort study (CHRYSALIS) revealed that amivantamab has effective and safe therapeutic potential in EGFR ex20ins NSCLC (66).